FE 201836

Drug Profile

FE 201836

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ferring Pharmaceuticals
  • Class Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nocturia

Most Recent Events

  • 27 Jul 2017 Phase-II clinical trials in Nocturia in Hungary (PO) (EudraCT2016-003851-31)
  • 27 Jul 2017 Phase-II clinical trials in Nocturia in USA (PO) (NCT03201419)
  • 05 Jul 2017 Ferring Pharmaceuticals plans a phase II trial for Nocturia in July 2017 (NCT03201419)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top